|
|
Cancer immunotherapy is poised to become treatment option in many cancers. The group is formed in order to keep clinical results posted to help clinicians make informed decisions. It would be an interactive platform to post queries, advises and discontent that could be reviewed by any one joining the group.
April 26-
February 20-
Welcome Prem Ravi Varma about 4 months ago  Prem Ravi VarmaPlease let me know if this treatment is possible in the government hospital setting in India and how to get trained in Dendritic cell therapy.
August 27-
 |
Jamal Khan
DENDRITIC CELL THERAPY MEETS RECIST CRITERIA
Dendritic cell (DC) therapy has often been neglected as a standard line of care among oncologists. This is because of its failure to produce evidences in relation to reduction in tumor load. Immunotherapists aim to prove that DC therapy results in halting tumor progression and increasing life span, but these terms remain subjective to verification. On the contrary, the oncologists have their own version of depicting positive changes in post-treated patients of chemotherapy. According to them, when chemotherapy has been stopped, patients feel better as they no more experience the AE, the appetite improves and the benefits of chemotherapy make the disease stable.
So, to prove the worthiness of DC therapy, it is important to show that the recipients have lived for years in stage IV disease, or that there is a radiological evidence of reduction in tumor load.
Our recent trial of DC in combination with losartan and low dose bevacuzimab (DCLB) is proving that the DC therapy clears the tumor load and improves terminally ill patients also.
We inducted four patients in a DCLB trial all with different cancers and in advanced stages. They are showing improvement in their general well being. The tumor load has reduced ranging from 20 to 30% in each of the cases till date.
On my recent visit to ASCO annual conference, I gathered from Dr. Rakesh K. Jain, the importance of managing tumor microenvironment in treating cancer. His speech, based on his research of 40 years has given me an impetus to translate it into clinical practice. Based on this, we are now including losartan and bevacuzimab to normalize the tumor microenvironment. This has helped to improve the outcome in above-mentioned cases.
The results would be published as soon as we close the study.
about 9 months ago
| | |
-
Jamal Khan updated the group
February 17-
December 02-
October 25-
Jamal Khan updated the group
October 17-
October 07-
October 03-
Welcome Fatina Altahan about 2 years ago  Jamal KhanWelcome, Please indicate your inerests in this group and your field of work.
September 10-
September 09-
Welcome Ratnavelu Kananathan about 2 years ago  Ratnavelu KananathanI would like to take this opportunity to thank Dr Jamal for creating this group.
I am a Medical oncologist from Malaysia .
I feel strongly the way to go in future lies with our cell.
There is an explosion of trials then have started in non small cell as well as ovary apart from the established prostate cancer.
To Dr Jamal how are we going to use this platform to further the cause?
Jamal KhanDear Dr. Kananathan
Thanks for your signing to the group. You have used the personalized dendritic cell therapy for some of your patients in Malaysia. Your case reports have been published in Malaysian Oncology Society Conference.
We have to tell to the fellow oncologists about the safety of the protocol, that is very important and secondly about its efficacy ONLY when it is prescribed at right stage, i.e. at minimal tumor load.
I think that would be the best way to use this platform for strengthening the cause.
Due to my participation in Coneference on Cancer Immunotherapy in NIH, I could not reply to you earlier.
September 02-
September 01-
Jamal Khan updated the group
August 29-
August 18-
|
Jamal Khan
The Group awaits members
Hi! I am inviting all Oncologists on Earth to join this group. They would know more about the cancer immunotherapy in the form of dendritic cell therapy. I shall provide you details of my own results.
about 2 years ago
| | |
-
|